Tirzepatide vs Semaglutide

Tirzepatide and semaglutide sit at the top of the GLP-1 conversation for good reason: both produce weight loss numbers that simply did not exist in pharmacology a decade ago. They're often discussed as interchangeable, but they aren't. The molecules are different, and the trial results reflect that.

The short version: semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual agonist, hitting both the GLP-1 receptor and the GIP receptor. That second receptor target is the structural reason tirzepatide tends to outperform semaglutide on weight loss in head-to-head and parallel trials.

That doesn't make one drug "better" universally. It makes them better at different things, with different side effect profiles, different prices, and different supply situations.

At a glance

How they're alike

Both drugs are once-weekly subcutaneous injections that work primarily by slowing gastric emptying, signaling satiety to the brain, and improving insulin response. Both come in pre-filled pen devices and follow a multi-month titration to a maintenance dose.

The side effect families overlap heavily. Nausea, constipation, diarrhea, fatigue, and a temporary dip in appetite are common in the first few weeks on either drug. Severe but rare risks (pancreatitis, gallbladder issues, and the boxed thyroid C-cell warning carried over from animal data) appear on both labels.

Both drugs also share the same fundamental insight about obesity treatment: weight comes back when you stop. Trials of both medications show meaningful weight regain after discontinuation, which is why providers usually frame them as long-term therapies, not short courses.

How they're different

Mechanism is the headline. Semaglutide binds the GLP-1 receptor only. Tirzepatide binds both GLP-1 and GIP. The added GIP activity is associated with better insulin sensitivity and, in trials so far, larger weight reductions at the highest dose.

Efficacy follows from that. SURMOUNT-1 reported a mean body weight reduction of about 20.9 percent at 72 weeks at the 15 mg dose of tirzepatide. STEP 1 reported about 14.9 percent at 68 weeks on semaglutide 2.4 mg. SURMOUNT-5, a head-to-head trial released by Eli Lilly in 2025, also favored tirzepatide over semaglutide on weight loss endpoints. Individual response varies — some people lose more on semaglutide than on tirzepatide — but population-level data tilt toward tirzepatide.

Side effect intensity at high doses differs in a few ways. Tirzepatide discontinuation rates rose sharply with dose (around 25 percent at 15 mg in SURMOUNT-1, versus around 5 percent at 5 mg), suggesting that the upper dose is not universally tolerable. Semaglutide tends to plateau in side effect intensity earlier because the dose range is narrower. Cost and insurance coverage vary by brand, prescriber, and plan — neither is cheap without coverage.

Which one is right for you?

If your insurance and provider give you a choice, the case for tirzepatide rests on the larger average weight loss in trials. The case for semaglutide rests on a longer track record (it has been approved since 2017 in the diabetes formulation) and broader real-world data.

Practical questions usually settle it: which one does your insurance cover? Which is in stock at your pharmacy? Which has a savings program your prescriber can route you to? How well are you tolerating the side effects? People who do not tolerate the top dose of one often do better on a different dose of the other. This is a decision to make with your clinician, with realistic expectations about both trial numbers and your own physiology.

Common questions

Keep exploring

Browse all GLP-1 guides or read about the best GLP-1 for weight loss in 2026.